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Ontario, CanadaABSTRACT Human serum albumin (HSA) is a potent inhibitor of Ab self-association and this novel, to our knowledge, function
of HSA is of potential therapeutic interest for the treatment of Alzheimer’s disease. It is known that HSA interacts with Ab
oligomers through binding sites evenly partitioned across the three albumin domains and with comparable affinities. However,
as of this writing, no information is available on the HSA-Ab interactions beyond domain resolution. Here, we map the HSA-Ab
interactions at subdomain and peptide resolution. We show that each separate subdomain of HSA domain 3 inhibits Ab self-
association. We also show that fatty acids (FAs) compete with Ab oligomers for binding to domain 3, but the determinant of
the HSA/Ab oligomer interactions are markedly distinct from those of FAs. Although salt bridges with the FA carboxylate
determine the FA binding affinities, hydrophobic contacts are pivotal for Ab oligomer recognition. Specifically, we identified a
site of Ab oligomer recognition that spans the HSA (494–515) region and aligns with the central hydrophobic core of Ab. The
HSA (495–515) segment includes residues affected by FA binding and this segment is prone to self-associate into b-amyloids,
suggesting that sites involved in fibrilization may provide a lead to develop inhibitors of Ab self-association.INTRODUCTIONLate-onset Alzheimer’s disease is associated with impair-
ment in the clearance of the amyloid beta (Ab) peptide
(1–8). The Ab peptide clearance from the brain relies on
the Ab transport through the blood-brain barrier promoted
by agents that do not penetrate the blood-brain barrier, but
bind Ab in plasma. Such agents drive an equilibrium shift
of Ab from the brain toward the periphery, as posited by
the peripheral-sink hypothesis (9). Because ~90% of
circulating plasma Ab is bound to human serum albumin
(HSA), HSA is a key mediator of Ab clearance. The pivotal
role of albumin in Ab clearance is also confirmed by recent
clinical investigations showing that low concentrations of
albumin in plasma are associated with cognitive impairment
(10,11). Moreover, albumin replacement through plasma
dialysis has been proposed as a promising strategy for
the treatment of mild Alzheimer’s disease (12). Given the
physiological and potential therapeutic relevance of the
Ab-albumin interactions, the stoichiometry and affinity of
the Ab-albumin complexes have been recently investigated
(13). These investigations have revealed that albumin selec-
tively targets Ab oligomers (denoted here as Abn) rather thanSubmitted July 5, 2013, and accepted for publication August 20, 2013.
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0006-3495/13/10/1700/10 $2.00Abmonomers (denoted here as Ab1) (13). The Ab oligomers
are recognized by albumin through largely independent
binding sites evenly partitioned across the three albumin
domains (Fig. 1 a) and with comparable dissociation con-
stants in the sub-mM range (13). Such degeneracy in the
Ab binding sites within albumin implies that each single
albumin domain can be used as a model system to further
probe the HSA/Ab interactions. However, the binding sites
for the Ab oligomers within HSA have not been mapped
beyond domain resolution, due to experimental challenges
arising from the transient nature and the high molecular
weight (MW) of the Ab oligomers interacting with HSA.
Here, we show how the interactions of domain 3 of HSA
with Ab oligomers can be mapped at subdomain and peptide
resolution.We specifically focus on domain 3 (i.e., HSA381–
585), because it remains well structured and soluble even
when in isolation (13,14). In addition, domain 3 includes
high-affinity fatty-acid (FA) binding sites and therefore it is
a suitable construct to explore the competition between Ab
oligomers and FAs, such as myristic acid (MA). Because
the binding of MA to domain 3 has been structurally well
characterized (Fig. 1 b) (15–19), the MA-versus-Ab com-
petition is an effective approach to start mapping the Ab/
domain-3 interactions. However, given the presence of
multiple MA binding sites and the possibility of indirect
allosteric effects, competitive binding and inhibition experi-
ments alone are not sufficient to narrow down the Ab binding
sites within domain 3. We therefore complement the FA-
versus-Ab competition experiments with comparative muta-
tional analyses. Mutants include subdomain deletions (i.e.,
subdomains 3A and 3B) and point mutations within each sub-
domain at sites of FA binding. The combination of com-
parative mutational analyses and competition experimentshttp://dx.doi.org/10.1016/j.bpj.2013.08.025
FIGURE 1 X-ray crystal structures of HSA-
bound myristic acid (PDB:1E7G). Myristate mole-
cules are shown in space-filling representation and
are colored by atom: carbon (black), oxygen (red).
Major drug binding sites are labeled as Sudlow’s
sites I and II and their location in the 2A and 3A
subdomains, respectively, is indicated. (Inset)
Detail of the structures of domain-3, subdomains
3A (blue), 3B, and the HSA (495–515) segment
(orange), for which the Ab interactions were inves-
tigated here. To see this figure in color, go online.
Mapping Ab-HSA Interactions’ 1701monitored byNMRprovides a viable experimental strategy to
effectively circumvent the challenges inmapping interactions
with large and transient Ab oligomers.
Our results show that FAs compete with Ab oligomer for
binding to domain 3 of HSA and that, similarly to FAs, Ab
oligomers interact with both subdomains 3A and 3B,
although not all the residues critical to bind FA interact
with the Ab oligomers. In addition, we took our reductionist
approach one step further and we identified, using a
combination of bioinformatics and fluorescence, a con-
tiguous putative Ab interaction site in subdomain 3B. The
subdomain-3B peptide spanning the identified Ab interac-
tion site was synthesized and tested for self-association
inhibitory potency. The selected domain-3 peptide inhibits
Ab self-association and interestingly matches well with a
region of albumin prone to amyloid fibril formation. These
results suggest the intriguing hypothesis that a subset of the
putative sites of Ab-binding proteins involved in inter-
molecular contacts during protein self-association may
also serve as possible Ab recognition and inhibition sites.MATERIALS AND METHODS
Ab (12–28) peptide sample preparation
The Ab (12–28) peptide used in this investigation was purchased from Pep-
nome (Zhuhai City, China)with a purity of 98%. Lyophilized peptidewas dis-
solved in 50-mMacetate buffer-d4 at pH4.7,with 10%D2O to a concentration
of 1 mM. After the peptide was dissolved, the solution was filtered through
an Ultrafree-MC filter (Millipore, Billerica, MA) with a 30-kDa cutoff in
5-min intervals at 3000 rpm to remove aggregates formed during the peptide
lyophilization and dissolution processes (13,20–22). To induce aggregation
a 1-M NaCl solution prepared in 50-mM acetate buffer at pH 4.7 was then
added to the filtered peptide sample up to a final concentration of 40-mM
NaCl, followedbya seven-day incubationperiod at room temperature (13,21).Ab (1–42) peptide sample preparation
The Alzheimer’s peptide Ab (1–42) was purchased from EZBiolab
(Carmel, IN) with a purity>95%. A stock Ab (1–42) solution was preparedby dissolving 5 mg of the Ab (1–42) peptide in 2.5 mL of 10 mM NaOH
(13,22). This stock solution was sonicated twice using 2-min intervals
followed by 2-min incubation on ice. Immediately after sonication, the
stock Ab (1–42) solution was divided into 100-mL aliquots and frozen
at20C. A quantity of 100 mL of the Ab (1–42) stock solution was thawed
and sonicated twice for 2 min with 2-min incubation on ice in-between
before each experiment. A quantity of 450 mL of wild-type domain 3,
domain 3 bound to myristic acid, and domain-3 mutant proteins in
20-mM sodium phosphate buffer at pH 7.4 was added to the sonicated
peptides for collection of NMR spectra at 700 MHz with a TCI CyroProbe
(Bruker BioSpin, Billerica, MA) and at 37C. During the time between
NMR data acquisition sessions, the NMR samples were stored in a water
bath at 37C and were not stirred or mixed.Trifluoroacetic acid removal from the Ab samples
Although all peptides were commercially obtained with >95% purity,
they all contained residual trifluoroacetic acid, which is routinely used in
the final stage of peptide purification. To avoid potential biases, trifluoro-
acetic acid was removed from the Ab samples before the addition of
the domain 3 using at least three lyophilization steps in the presence of
50–100 mM HCl (23).Preparation of human serum albumin peptides
Human serum albumin (HSA) peptides, HSA (495–515), HSA (495–515)
reversed, and HSA (530–550) were purchased from GenScript USA
(Piscataway, NJ) as a dry powder with purity >95%. A quantity of 0.5-mM
peptides stock solutions was prepared by dissolving the lyophilized powder
in water and adding 50 mM NaOH until the peptides were fully solubilized.
Peptides concentration was determined by measuring their UV absorbance
at 280 nm using 1490 M1 cm1 as extinction coefficient.Preparation of myristic-acid stock
Myristic acid (MA) dry powder (Sigma 490873; Sigma-Aldrich, St. Louis,
MO) was dissolved in DMSO-d6 at 100 mM. Afterwards aliquots of
myristic acid were diluted to 1.5 mM in 20 mM sodium phosphate, pH
7.4 at 70C. The stock was then cooled to 55C and stored at that temper-
ature for use in subsequent experiments. The myristic acid concentration
was confirmed based on the comparison of the methyl signal intensity of
the myristic acid 1H-NMR spectra to the methyl intensity of an octanoic
acid internal standard (Sigma 153753; Sigma-Aldrich).Biophysical Journal 105(7) 1700–1709
1702 Algamal et al.Protein subcloning, expression, and purification
The domain-3 gene flanked by the NdeI restriction enzyme site and six
histidines at the N-terminus was generated in the pet15B vector, as
previously published in Milojevic and Melacini (13). The Y411AR410A,
R485AS489A, and K525A mutants were generated following standard
PCR protocols. The 3A subdomain was generated by mutating T496 into
a stop codon using as a primer
5
0
GCTCTGGAAGTCGATGAATAATACGTTCCC 3
0
:
The 3B construct was generated by mutating D494 and E495 into an NdeI
restriction enzyme site. This was accomplished using the primer
5
0
CAGCTCTGGAAGTCCATATGACATACGTTCCC 3
0
:
Because the 3A subdomain was flanked by the NdeI site, digestion of this
mutated DNA resulted in the excision of the 3A subdomain from the
domain-3 sequence. Subsequent ligation generated a 3B subdomain DNA
construct. The sequence of each constructs was confirmed through
PCR-based sequencing. All proteins samples were expressed and purified
as previously described in the literature (13,14).
NMR spectroscopy
One-dimensional saturation transfer difference (STD) and saturation
transfer reference (STR) experiments were used to monitor the effect of
domain-3 mutants and deletion constructs on the Ab (12–28) samples. In
the STD measurements, saturation is transferred through chemical ex-
change from the Ab (12–28) oligomers to the monomeric, and thus
NMR-detectable, Ab (12–28). Hence, the STD signal probes the interac-
tions of monomeric Ab (12–28) polypeptide chains with the Ab (12–28)
assemblies. Albumin competes with monomeric Ab (12–28) for binding
to oligomeric Ab (12–28), resulting in a loss of STD signal that is
albumin-concentration dependent and is exploited to measure the effective
average affinity of albumin for the Ab (12–28) assemblies. A previously
published experimental setup was used from Milojevic and Melacini
(13), and therefore will not be further discussed here. The titration curves
were fitted using a Scatchard-like model as previously explained (13).
Due to the transient nature of the oligomers formed by the longer Ab
(1–42) peptide, the STD experiments were not performed for this longer
peptide; however, the intensities of one-dimensional Watergate experiments
are effective in probing aggregation of Ab (1–42) (13,22). These experi-
ments rely on the incorporation of a 30-ms-long spin-lock pulse before
acquisition to suppress contributions from residual protein and selectively
observe the monomeric and low MW Ab signals. All experiments were
acquired on an Avance 700 MHz spectrometer (Bruker BioSpin) equipped
with a 5-mm TCI CyroProbe (Bruker BioSpin). The STD experiments were
performed at 20C, whereas one-dimensional watergate water-suppression
NMR technique experiments were performed at 37C. All spectra were
processed with the program NMRPIPE (24) and analyzed with the software
SPARKY (25).Thioflavin T fluorescence
Thioflavin T (ThT) fluorescence spectra were recorded using a Safire
fluorescence spectrometer (Tecan/Life Technologies, Carlsbad, CA) and
96-well plates (half-area) with 155-mL sample volumes (22,26). The con-
centration of Ab (1–42) in all samples was 70 mM, whereas the con-
centration of inhibitory and control peptides, i.e., HSA (494–515) and
HSA (594–515) reversed, respectively, was set to 120 mM. Measurements
were performed in 30 mM HEPES buffer with 20 mM of the ThT dye at
pH 7.4. As a control, individual ThT fluorescence spectra were collected
for HSA peptides samples. These values were subtracted from the values
obtained from the HSA peptides:Ab mixtures. For each sample, at leastBiophysical Journal 105(7) 1700–1709three measurements were performed and the average values are reported.
The error was calculated as the standard deviation of all measurements.Bioinformatics analysis
Secondary structure elements and local (three residues) root mean-square
deviation changes were calculated through the MOLMOL software (27)
using Protein Data Bank codes PDB:1AO6 and PDB:1E7G for apo and
MA-bound HSA (18), respectively. The Waltz algorithm (http://waltz.
switchlab.org/) was used to predict domain-3 regions prone to amyloid
formation (28). For the Waltz profile, the output with high sensitivity and
pH 7 was chosen. The Waltz score was plotted against the residue number
to show the residue-specific propensity of amyloid formation.RESULTS
Myristic acid and Ab oligomers compete for
binding to domain 3 of HSA
To probe the competition between MA and Ab binding,
we measured the potency of HSA domain 3 in inhibiting
Ab (1–42) self-association in the presence and absence of
MA. For this purpose, we monitored the loss of Ab (1–42)
one-dimensional NMR signal intensity versus time due to
the formation of high-MW NMR-undetectable aggregates
(Fig. 2 a). In these experiments, the contributions to the
NMR signal arising from HSA are effectively edited out
through a spin-lock relaxation filter. This is a distinct
advantage of NMR relative to other spectroscopies, such
as ThT fluorescence, because the ThT fluorophore binds
to HSA and therefore the addition of HSA may affect the
detected fluorescence signal. In addition, the Ab (1–42)
one-dimensional NMR signal intensity versus time profiles
appear more reproducible than those obtained using ThT
fluorescence (13,22,29), thus facilitating the quantitative
evaluation of self-association inhibitors through com-
parative analyses.
Fig. 2 a shows that in the absence of HSA domain 3, the
one-dimensional NMR signal of Ab (1–42) is rapidly lost
over time, until a plateau is reached with the original inten-
sity reduced by ~40%. Upon addition of substoichiometric
amounts of apo HSA domain 3, the NMR signal intensity
of Ab (1–42) is dramatically increased both in the initial
decay phase and in the final plateau region (Fig. 2 a), clearly
indicating that the isolated domain-3 functions as an effec-
tive Ab self-association inhibitor. However, when HSA
domain 3 was added in the presence of excess MA, the
inhibitory potency of domain 3 was significantly reduced,
resulting in Ab (1–42) signal intensities that are intermedi-
ate between those of the two previous profiles (Fig. 2 a).
These variations in the one-dimensional NMR signal versus
time profiles are attributable to either the competition
between MA and Ab (1–42) for binding to domain 3 and/
or to potential interactions between free MA and Ab
(1–42). To rule out the latter explanation, we monitored
the one-dimensional NMR signal of Ab (1–42) over time
in the absence and presence of 30 mM of MA and no
FIGURE 2 (a) Effect of myristic acid (MA) on the inhibition of Ab
(1–42) aggregation by HSA domain 3 (i.e., HSA 381–585). One-dimen-
sional 1H-NMR signal intensities of 90 mM Ab (1–42) recoded over time
are shown in the absence (solid circles) and in the presence of domain 3
either in the apo form (open circles) or saturated with MA (shaded circles).
The initial (t¼ 0) amplitude quantifies the NMR-detectable species present
after the dead time of the experiment, i.e., the time interval elapsed between
sample preparation and the beginning of the NMR data acquisition. The Ab
(1–42) concentration of 90 mMwas chosen because, under our experimental
conditions, it provides an optimal compromise between the signal/noise of
each sampled spectrum and the time resolution of the decay. We recognize
that this concentration is higher than those typically reported for in vivo Ab
(i.e., lower than nanomolar in human plasma (10)). However, our in vitro
conditions allowed us to test the effect of albumin on a wide range of Ab
assemblies from monomers to fibrils, increasing the likelihood to mimic
also the Ab association states relevant in vivo. (b) STR and STD spectra
for apo Domain 3 were subtracted from the respective spectra at each
titration point.
Mapping Ab-HSA Interactions’ 1703significant differences were observed upon addition of 30
mM of MA (see Fig. S1 in the Supporting Material). This
MA concentration exceeds the concentration of free MA
expected under the conditions of Fig. 2 a (i.e., [HSA
domain 3]Total ¼ 25 mM and [MA]Total ¼ 90 mM), because
domain 3 is fully saturated by MA, as shown by saturation
transfer difference NMR (Fig. 2 b) and the HSA domain
3:MA specific binding stoichiometry is 1:3. We therefore
conclude that the data of Fig. 2 b point to competition
between MA and Ab (1–42) oligomers for binding to
domain 3 of HSA.
The MA-versus-Ab competition emerging from Fig. 2 a
suggests that at least some of the domain-3 residues affected
by MA binding are also critical for Ab self-association inhi-
bition. The residues affected by MA binding include those
in direct contact with MA as well as those indirectly affectedby MA through local conformational changes (see Fig. S2).
Fig. S2 shows that the MA binding sites in domain 3 span
both subdomains (i.e., 3A and 3B) and that the sites directly
or indirectly affected by MA binding are scattered through
domain 3. Considering the abundance and wide distribution
of domain-3 sites affected by MA (see Fig. S2), we decided
to further narrow down the location of sites critical for Ab
self-association inhibition by complementing the competi-
tion experiments of Fig. 2 with comparative mutational
analyses.
The first set of mutants was designed to address the ques-
tion as to whether Ab binds both subdomains (i.e., 3A and
3B), similarly to MA, or it is selective for a single subdo-
main. For this purpose, we have subcloned, expressed, and
purified separate 3A and 3B subdomain constructs and tested
their interactions with two Ab peptides, Ab (12–28) and Ab
(1–42). The former peptide spans the central hydrophobic
core of the Ab peptide as well as key residues involved in
HSA binding (13,21,22) and was included in the analyses,
because unlike Ab (1–42), it forms stable soluble Ab oligo-
mers. Furthermore, the binding of Ab (12–28) oligomers to
albumin can be monitored by STD NMR experiments,
resulting in albumin inhibition isotherms from which quan-
titative effective KD values for the Ab oligomer:HSA com-
plexes are obtained based on Scatchard-like models, as
previously explained (13). In addition, the Ab (12–28)
STD-versus-[HSA] inhibition profiles exhibit a clear plateau
whose starting point provides an estimation of the effective
concentration of protein (i.e., HSA) necessary to saturate
the Ab (12–28) oligomers binding sites (13).Subdomains 3A and 3B are minimal structural
units that retain potency in inhibiting Ab
self-association
Fig. 3, a and b, shows the concentration-dependent STD-
monitored Ab (12–28) self-association inhibition profiles
measured for subdomains 3A and 3B. The STD-monitored
titration data (Fig. 3, a and b) display a typical dose-
response pattern in which ISTD/ISTR decrease progressively
as the subdomain concentration increases, until a saturation
plateau is reached, indicating that both subdomains span
specific Ab oligomers binding sites. These interactions are
compatible with at least two different stoichiometries for
the domain 3:Abn complexes. In the first stoichiometry, a
single Ab oligomer interacts with both subdomains. In
this case, we expect that, in going from the integral domain
3 to the separate subdomains, the average effective number
of Ab oligomers bound per molecule of albumin construct,
defined as nAbn, will remain largely unaffected, although the
affinity may change. In the second putative stoichiometry,
two distinct Ab oligomers interact with the two subdomains.
In this case, we expect that, in going from the integral
domain 3 to the separate subdomains, nAbn should approxi-
mately halve.Biophysical Journal 105(7) 1700–1709
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FIGURE 3 Inhibition of the Ab self-association
by domain 3 and its subdomain deletion mutants
monitored by dose-response Ab (12–28) STD-
based profiles (a–c) and by Ab (1–42) one-dimen-
sional NMR versus time (d). (a–c) Effect of the
subdomain deletion mutants (i.e., 3A and 3B) and
the full-length domain 3, respectively, on the
relative ISTD/ISTR ratios measured for a filtered
1-mM Ab (12–28) peptide sample aggregated
through addition of 40 mM of NaCl. (Dotted,
dashed, and solid lines) Dose-response curves
backcalculated using a Scatchard-like model. In
each panel the structure of domain 3 is shown
(PDB:1A06); (black) construct used in the titration.
h[Abn]Toti: The average effective total concentra-
tion of albumin-binding competent Ab oligomers
and g ¼ nprotein/nAbn, where nprotein is the average
effective number of albumin protein construct
molecules (i.e., domain 3 or subdomain 3A or
3B) bound per Ab oligomer and nAbn is the average
effective number of Ab oligomers bound per mole-
cule of albumin protein construct. (d) 0.1 mM Ab
(1–42) samples were incubated with 10 mM of
domain-3 constructs and changes in the intensities
of the methyl region of one-dimensional watergate
spectra with time are reported. All intensities were
normalized to the 0.1-mM Ab (1–42) sample
acquired for the first incubation time point.
1704 Algamal et al.To discriminate between the two possible domain 3:Abn
stoichiometries discussed above, we also measured as a
reference the Ab (12–28) self-association inhibition STD
profile for the integral domain 3 (Fig. 3 c). All three STD
profiles of Fig. 3, a–c, were fitted to a Scatchard-like model,
which provides the gh[Abn]Toti product (13), where
h[Abn]Toti is the average effective total concentration of
albumin-binding competent Ab oligomers. Here, g ¼
nprotein/nAbn, where nprotein is the average effective number
of albumin protein construct molecules (i.e., domain 3 or
subdomain 3A or 3B) bound per Ab oligomer, and nAbn is
defined as above, i.e., the average effective number of Ab
oligomers bound per molecule of albumin construct (13).
Because the measurements in Fig. 3, a–c, were recorded
utilizing the same Ab stock solution, h[Abn]Toti does not
change appreciably in the inhibition STD profiles of domain
3 and subdomains 3A and 3B (Fig. 3, a–c). Similarly, nprotein
is not expected to vary in going from panels a–c of Fig. 3
and to be ~1, as previously reported (13). As a result, vari-
ations in the fitted gh[Abn]Toti product across the three
panels of Fig. 3, a–c, report primarily on changes in nAbn,
allowing us to differentiate between the two proposed puta-
tive stoichiometries for binding of Ab oligomers to domain
3 of albumin.
The comparison of the STD profile in Fig. 3 cwith those in
Fig. 3, a and b, clearly shows that in going from domain 3 to
the either one of the two separate subdomains, gh[Abn]Toti
is doubled (Fig. 3, a–c), as expected if the nAbn value of
domain 3 is approximately twice the nAbn value for the iso-
lated 3A or 3B subdomains. These observations supportBiophysical Journal 105(7) 1700–1709the second stoichiometric pattern, whereby each subdomain
binds a different Ab (12–28) oligomer. This conclusion is
also consistent with the inhibitory potencies measured for
the two subdomains using the longer Ab (1–42) peptide
(Fig. 3 d). Fig. 3 d consistently indicates that domain 3
exhibits higher inhibition potency than the individual subdo-
mains, corroborating that both subdomains, 3A and 3B, are
involved in Ab oligomer binding. Given that each subdo-
main interacts with Abn, the next open question we focused
on pertains to the specific Abn contact sites within each HSA
subdomain.Comparison of Ab and fatty acid binding modes:
effects of hydrogen-bonding perturbing
mutations
Given the competition between fatty acids (FAs) and Ab
oligomers supported by Fig. 2, we hypothesized that Ab
and FAs might share common binding determinants. To
test this hypothesis, we investigated the interaction between
Ab and domain-3 mutants that hamper FA binding by
removing side chains involved in hydrogen bonds to the
FA carboxylate. For instance, the R410A/Y411A and
R485A/S489A double mutations (Fig. 4, b and d) drastically
reduce fatty-acid binding to subdomain 3A (see Fig. S3, a
and b), whereas K525A (Fig. 4 f) markedly decreases
FA binding to subdomain 3B (see Fig. S3 c) (17).
Therefore, we tested the interactions of these three sets of
domain-3 mutants (i.e., R410A/Y411A, R485A/S489A,
and K525A) with Ab oligomers. Fig. 4, a, c, and e, reports
FIGURE 4 Inhibition of the Ab self-association
by fatty acid silencing domain-3 point mutants
monitored by dose-response Ab (12–28) STD-
based profiles (a–f) and by Ab (1–42) one-
dimensional-NMR versus time (g). (a, c, and e)
All ratios were normalized to their maximum value
measured before protein addition. (Dashed, solid,
and dotted lines correspond to dose-response
curves backcalculated using a Scatchard-like
model and KD values of 1, 5, and 10 nM, respec-
tively.) (Red) In each panel, for reference purposes,
the titration profile of wild-type domain 3, mea-
sured using the same Ab (12–28) peptide batch
as the mutated protein, is shown in red. (b, d, and
f) Side chains of the mutated residues interacting
with fatty acids. (Yellow) Bound fatty acids.
(Dashed lines) Hydrogen bonds to the fatty acid;
their lengths are reported in A˚ngstroms. For panel
d, experiments were acquired at 700 MHz at 310 K
in 20 mM potassium phosphate, pH 7.4, 10% D2O,
0.05% NaN3. A 50-ms-long spin lock was used to
suppress residual protein signal. Color coding is as
per the legend in the figure. To see this figure in
color, go online.
Mapping Ab-HSA Interactions’ 1705the STD-monitored titration of Ab (12–28) with the R410A/
Y411A, R485A/S489A, and K525A domain-3 mutants. The
STD profiles shown in Fig. 4, a, c, and e (black dots),
indicate that all three domain-3 mutants are active inhibitors
of Ab (12–28) self-association. Furthermore, no significant
differences were observed when the titration profile of each
mutant was compared to the corresponding profile for the
wild-type domain 3 (Fig. 4, a, c, and e, red dots). These
results suggest that mutations that disrupt the interactions
of domain 3 with FAs (see Fig. S3) do not necessarily affect
Ab (12–28) oligomer binding, pointing to marked differ-
ences between the HSA binding determinants for FAs and
those for the Ab (12–28) oligomers. To confirm the validity
of this conclusion for longer and more physiologically
relevant Ab peptides, we also tested the interactions
between the three domain-3 mutants and Ab (1–42).The experiments on the Ab (1–42) peptide (Fig. 4 g)
confirmed the differences between the Ab and FA binding
modes already emerged from the STD experiments on Ab
(12–28) (Fig. 4, a, c, and e). Specifically, Fig. 4 g indicates
that the incubation of Ab (1–42) at 37C results in peptide
aggregation and consequent losses in the Ab NMR signal
over time. These signal losses are significantly reduced in
the presence of wild-type domain 3 (Fig. 4 g). A similar
reduction in aggregation is observed for all domain-3
mutants, suggesting that the mutations did not significantly
perturb binding of the Ab oligomers to domain 3 (Fig. 4 g),
although they had a marked effect on FA binding (see
Fig. S3) (17). We conclude that the mutated residues (i.e.,
R410, Y411, S489, R485, and K525), although involved
in hydrogen bonds with albumin-bound FAs, are not part
of the HSA domain-3 determinants for Ab binding. ToBiophysical Journal 105(7) 1700–1709
1706 Algamal et al.further dissect the domain-3 residues involved in Ab bind-
ing, we focused on subdomain 3B, because it provides a
minimal structural unit that still inhibits Ab self-association
(Fig. 3, a and d) and it includes only a single well-defined
FA binding site.Dissecting the subdomain-3B determinants for
Ab binding
As a first step toward narrowing down the Ab binding sites
within subdomain 3B, we verified that this construct retains
FA binding capacity and that FA binding competes with Ab
binding. Fig. S4 a shows the STD amplification factor for a
titration of MA into subdomain 3B. A clear dose-response
pattern with plateau is observed, confirming that MA binds
specifically to our 3B construct. Furthermore, Fig. S4 b,
similarly to Fig. 2 a, clearly shows that MA binding
decreases the Ab self-association inhibitory potency of the
3B construct, indicating that the MA-versus-Ab oligomer
competition occurs also at the level of subdomain 3B.
This observation suggests that the 3B residues interacting
with the Ab oligomers are either in direct contact with the
FA (see Fig. S2, open circles) and/or are indirectly affected
by FA binding through conformational changes (see Fig. S2,
local root mean-square deviation).
To further screen for the 3B sites that recognize Ab olig-
omers, we hypothesized that, because Ab monomers and
HSA compete for the same binding partner (i.e., Ab oligo-
mers), the recognition of Ab oligomers by HSA should to
some extent resemble the recognition of Ab oligomers by
Ab monomers. Based on this hypothesis, HSA residues
with high propensity to bind to Ab oligomers and proto-
fibrils should meet two additional criteria:
1). They should fall in regions of HSA prone to adopt a
b-strand conformation and to self-associate into
amyloid fibrils. For instance, the Waltz algorithm (28)
predicts that three distinct segments of subdomain 3BBiophysical Journal 105(7) 1700–1709are likely to be involved in HSA self-association
(Fig. 5 b), with the longest region spanning residues
494–515.
2). Sites that recognize Ab assemblies are likely to align in
sequence with the Ab residues involved in self-recogni-
tion. For instance, the central hydrophobic core of Ab
(i.e., L17VFFA21) is known to be critical for Ab self-
association and aligns well with several residues in the
494–515 segment of HSA (Fig. 5 c). Interestingly, the
494–515 region also includes several loci of FA-
dependent conformational change (see Fig. S2).
Overall, the 494–515 HSA segment emerges as a
consensus sequence for Ab oligomer binding, which is
consistent with the MA competition data (see Fig. S4)
and meets the two bioinformatic criteria of amyloid pro-
pensity and Ab alignment (Fig. 5, b and c).
Based on these observations, we hypothesized that the HSA
(494–515) peptide retains Ab self-association inhibitory
potency. To test this hypothesis, we measured the inhibitory
potencies of the HSA (494–515) synthetic peptide using
both the Ab (12–28) and Ab (1–42) systems. We also
included in our measurements two negative controls, i.e.,
the reversed HSA (494–515) peptide, to check the speci-
ficity of the HSA peptide/Ab interactions, and the HSA
(530–550) peptide, which spans a region of subdomain 3B
that does not meet our two bioinformatic criteria (Fig. 5,
b and c).
Fig. 6 a shows the effect of the HSA (494–515) peptide
on the Ab (12–28) self-association as monitored by STD.
The STD-versus-[HSA (494–515)] profile conforms to a
clear dose-response pattern with a well-defined plateau
(Fig. 6 a), pointing to specific interactions between this
HSA peptide and Ab (12–28). The specificity of these inter-
actions is further confirmed by the dramatically reduced
affinity for Ab (12–28) observed for the reversed HSA
(494–515) peptide (Fig. 6 a), which results in an effective
Kd approximately one order-of-magnitude higher than thatFIGURE 5 (a) Subdomain-3B secondary struc-
ture (PDB:1E7G). (b) WALTZ scores, which
predict amyloid propensity (28). (c) CLUSTALW
(http://www.genome.jp/tools/clustalw/) sequence
alignment of subdomain 3B and Ab (12–28).
(Dashed line) Residues of no consensus; (stars)
single, fully conserved residues; (semicolons)
strong conserved residues; (dots) weak con-
served residues. (Shaded) Domain-3 regions cor-
responding to the HSA peptides (494–515) and
(530–550) used in Fig. 6.
FIGURE 6 (a) Dose-response STD-based profiles for the inhibition of
the Ab (12–28) self-association by three HSA domain-3-derived peptides,
i.e., HSA (494–515) (solid diamonds), HSA (494–515) with reversed
sequence (solid triangles), and HSA (530–550) (solid squares). The latter
two peptides serve as negative controls. (b) Inhibition of Ab (1–42) aggre-
gation by HSA (494–515) (open circles) and HSA (494–515) with reversed
sequence (solid circles), as monitored by ThT fluorescence. (Shaded
circles) Aggregation profile for Ab (1–42) alone.
Mapping Ab-HSA Interactions’ 1707measured for the wild-type HSA (494–515) counterpart
(Fig. 6 a). In addition, as expected, no Ab (12–28) self-
association inhibition was observed for the other negative
control peptide, i.e., HSA (530–550) (Fig. 6 a), confirming
the usefulness of the bioinformatic selection criteria.
The results obtained for Ab (12–28) (Fig. 6 a) were
confirmed when the HSA peptides were tested on Ab
(1–42) (Fig. 6 b). The self-association of Ab (1–42) was
not monitored by NMR intensity losses because of the over-
lap between the NMR signals of the Ab (1–42) and the HSA
(494–515) peptides. The sharp and intense NMR lines of the
flexible HSA (494–515) peptide are not easily edited out
through a spin-lock relaxation filter without significant in-
tensity losses for the Ab (1–42) peptide as well, unlike the
case of larger and well-structured HSA constructs. However,
unlike full-length HSA, the HSA (494–515) peptide under
our experimental conditions does not affect the fluorescence
of ThT in the absence of Ab (1–42) (see Fig. S5). We there-
fore resorted to ThT fluorescence to monitor the formation
of cross-b amyloid assemblies (Fig. 6 b). Fig. 6 b shows
that the HSA (494–515) peptide significantly reduces the
ThT fluorescence arising from the Ab (1–42) cross-b
amyloids formed during a 15-h incubation period. Thisinhibitory effect is completely lost when the HSA (494–
515) sequence is reversed (Fig. 6 b). Overall, the data for
Ab (12–28) and Ab (1–42) (Fig. 6, a and b) consistently
point to the HSA (494–515) region as a site of specific
HSA/Ab contacts, confirming our hypothesis based on the
FA competition experiments and bioinformatic analyses
(Fig. 5).DISCUSSION
The consensus model emerging from the data presented here
provides unprecedented insight about the HSA:Ab oligomer
interactions well beyond the previously available domain
resolution. We show that each separate subdomain of HSA
domain 3 retains Ab self-association inhibitory potency
and is able to bind Ab oligomers with a sub-mM affinity
(Fig. 3). The FA binding sites are also located in both
subdomains 3A and 3B (Fig. 1), and FAs compete with
Ab oligomers for binding to domain 3 (Fig. 2 and see
Fig. S4). However, the determinant of the HSA/Ab oligo-
mers interactions is markedly distinct from those of FAs
(Fig. 4). For FAs, although extensive hydrophobic contacts
are common, it is the strength of hydrogen bonds/salt
bridges formed between the albumin amino-acid side chains
and the fatty acid carboxylate groups that determine the
binding affinities (see Fig. S3) (15,16). For Ab, the rele-
vance of these specific polar/ionic interactions becomes
marginal (Fig. 4), but hydrophobic contacts appear to play
a pivotal role for Ab oligomer recognition (Figs. 5 and 6).
For instance, in the case of subdomain 3B, a site of Ab
oligomer recognition spans the HSA (494–515) region,
which includes hydrophobic sites in contact with the
aliphatic tail of MA and subject to changes in conformation
upon FA binding (see Fig. S2). The (494–515) HSA region
thus explains the competition between FA and Ab oligomer
for binding to HSA subdomain 3B, although at this stage we
cannot rule out that other HSA sites may also contribute to
the observed FA-versus-Abn competition. Interestingly, the
(494–515) segment also includes several residues that align
to the central hydrophobic core sequence of Ab (i.e.,L17-
VFFA21, Fig. 5 c).
The importance of the hydrophobic effect in the binding
of Ab oligomers is supported by the observation that several
other Ab binding proteins, such as sLRP (30), clusterin
(31,32), and ApoE (33), are also involved in lipid binding.
Additionally, it was recently shown that binding of Ab to
proteins not involved in lipid metabolism, such as ABAD
and affibody ZAb3, is accompanied by a favorable entropic
change, consistent with hydrophobically driven protein:Ab
interactions (34–36). Furthermore, the solution structure
of the complex between Ab and the affibody ZAb3 dimer
revealed a large hydrophobic cavity, which is required for
high Ab affinity (36).
The observations that the HSA (494–515) peptide
inhibits Ab self-association (Fig. 6) and is also prone toBiophysical Journal 105(7) 1700–1709
1708 Algamal et al.self-association into cross-b fibrils (Fig. 5 b) suggest the
hypothesis that protein segments prone to b-strand forma-
tion and self-association into amyloid deposits may also
serve as sites that target Ab oligomers at their growing
loci, where Ab monomers would otherwise bind. This
notion is supported by the structure of the affibody ZAb3
bound to Ab, revealing that the Ab peptide interacts with
a b-strand of ZAb3 (36). Overall, the criteria of hydrophobic-
ity, b-strand propensity, and involvement in protein:protein
self-association emerging from our investigation of
albumin:Abn interactions will facilitate the initial screening
for peptide regions that may serve as potential inhibitors of
Ab fibrilization. In addition, we anticipate that the methods
and experimental approaches utilized here to map the
albumin:Abn interactions will be at least in part transferable
to other amyloid inhibitory systems (30–39).SUPPORTING MATERIAL
Five figures are available at http://www.biophysj.org/biophysj/supplemental/
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